Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label international switch study of prophylactic fitusiran in hemophilia A or B patients previously on factor or bypassing agent prophylaxis
CTR20182302Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Alnylam Pharmaceuticals. Started Jun 2019; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20182302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182302.